Hisun Pharmaceutical To Acquire Hisun Group’s Assets
This article was originally published in PharmAsia News
Executive Summary
Zhejiang Hisun Pharmaceutical will purchase its largest shareholder Zhejiang Hisun Group's TCM workshop assets, including 12,400 square meters of structural space and 16,100 square meters of land and production facilities. Valued at 58.46 million yuan ($8.53 million), the entire TCM workshop will be tapped to increase Hisun Pharmaceutical's manufacturing capacity of TCM products and help it realize a complete production chain. The company will issue less than 50 million A shares with par value of one yuan per share to raise funds not exceeding 650 million yuan ($94.9 million). The capital will be used to fund Hisun Pharmaceutical's antiparasite drug project, erythromycin production capacity expansion, production technology reform of new antitumor drugs and acquisition of Hisun Group's R&D assets. (Click here for more - Chinese Language)
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.